Guidance Statement On BRCA1/2 Tumor Testing in Ovarian Cancer Patients

Area of Science:

• Oncology
• Genetics
• Molecular Diagnostics

Background:

• The 2015 approval of poly (adenosine diphosphate-ribose) polymerase inhibitors (PARPi) for ovarian cancer has shifted BRCA1/2 testing paradigms.
• Patients are now tested for BRCA1/2 mutations for treatment decisions, not just familial risk assessment.
• Tumor testing is increasingly considered to identify patients with somatic BRCA1/2 mutations who may benefit from PARPi therapy.

Purpose of the Study:

• To review the challenges associated with BRCA1/2 testing in tumor tissue.
• To provide technical recommendations for accurate detection of germline and somatic BRCA1/2 mutations.
• To discuss considerations for integrating ovarian tumor genetic analysis into patient care pathways.

Main Methods:

• Review of technical and analytical challenges in analyzing DNA from formalin-fixed, paraffin-embedded specimens.
• Discussion of strategies for BRCA1/2 testing in tumor tissue.
• Consideration of ethical requirements and patient pathway integration.

Main Results:

• Formalin-fixed, paraffin-embedded specimens present significant technical difficulties for DNA analysis.
• Specific recommendations are needed for reliable BRCA1/2 testing in tumor samples.
• Integrating genetic analysis into patient care requires careful planning and ethical consideration.

Conclusions:

• Accurate BRCA1/2 testing in ovarian cancer is essential for PARPi therapy selection.
• Addressing technical challenges in tumor DNA analysis is critical for clinical utility.
• A comprehensive approach including technical, clinical, and ethical factors is necessary for effective implementation.